Gene therapy is entering the stage of initial clinical development to treat a growing number of inherited metabolic diseases. This review outlines the development of liver-directed gene therapy for diseases caused by deficiencies of enzymes that are primarily expressed in the liver and discusses the disorders that appear most promising for clinical translation.
Get full access to this article
View all access options for this article.
References
1.
TerheggenHG, LowenthalA, LavinhaF, et al.Unsuccessful trial of gene replacement in arginase deficiency. Z Kinderheilkd, 1975; 119:1–3.
2.
MillerAD, EcknerRJ, JollyDJ, et al.Expression of a retrovirus encoding human HPRT in mice. Science, 1984; 225:630–632.
3.
ApplegarthDA, TooneJR, LowryRB. Incidence of inborn errors of metabolism in British Columbia, 1969–1996. Pediatrics, 2000; 105:e10.
4.
SandersonS, GreenA, PreeceMA, et al.The incidence of inherited metabolic disorders in the West Midlands, UK. Arch Dis Child, 2006; 91:896–899.
5.
LevyHL. Newborn screening conditions: what we know, what we do not know, and how we will know it. Genet Med, 2010; 12:S213–S214.
6.
MazariegosG, ShneiderB, BurtonB, et al.Liver transplantation for pediatric metabolic disease. Mol Genet Metab, 2014; 111:418–427.
7.
TeckmanJ, PerlmutterDH. Conceptual advances in the pathogenesis and treatment of childhood metabolic liver disease. Gastroenterology, 1995; 108:1263–1279.
8.
TosoC, RisF, MenthaG, et al.Potential impact of in situ liver splitting on the number of available grafts. Transplantation, 2002; 74:222–226.
9.
NewsteadCG. Assessment of risk of cancer after renal transplantation. Lancet, 1998; 351:610–611.
RaperSE, ChirmuleN, LeeFS, et al.Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab, 2003; 80:148–158.
12.
WilsonJM. Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mol Genet Metab, 2009; 96:151–157.
13.
Hacein-Bey-AbinaS, Von KalleC, SchmidtM, et al.LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science, 2003; 302:415–419.
14.
BraunCJ, BoztugK, ParuzynskiA, et al.Gene therapy for Wiskott-Aldrich syndrome—long-term efficacy and genotoxicity. Sci Transl Med, 2014; 6:227ra33.
15.
RaperSE, YudkoffM, ChirmuleN, et al.A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum Gene Ther, 2002; 13:163–175.
16.
Brunetti-PierriN, PalmerDJ, BeaudetAL, et al.Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum Gene Ther, 2004; 15:35–46.
17.
MuruveDA, BarnesMJ, StillmanIE, et al.Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther, 1999; 10:965–976.
18.
NathwaniAC, TuddenhamEG, RangarajanS, et al.Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med, 2011; 365:2357–2365.
19.
NathwaniAC, ReissUM, TuddenhamEG, et al.Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med, 2014; 371:1994–2004.
20.
Gonzalez-AseguinolazaG. Augmenting PBGD expression in the liver as a novel gene therapy for acute intermittent porphyria (AIPgene). Hum Gene Ther Clin Dev, 2014; 25:61–63.
21.
Brunetti-PierriN, LiouA, PatelP, et al.Balloon catheter delivery of helper-dependent adenoviral vector results in sustained, therapeutic hFIX expression in rhesus macaques. Mol Ther, 2012; 20:1863–1870.
22.
Brunetti-PierriN, NgT, IannittiD, et al.Transgene expression up to 7 years in nonhuman primates following hepatic transduction with helper-dependent adenoviral vectors. Hum Gene Ther, 2013; 24:761–765.
SmithCA, WoodruffLS, KitchingmanGR, et al.Adenovirus-pulsed dendritic cells stimulate human virus-specific T-cell responses in vitro. J Virol, 1996; 70:6733–6740.
25.
Molinier-FrenkelV, Gahery-SegardH, MehtaliM, et al.Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes. J Virol, 2000; 74:7678–7682.
26.
WangL, FigueredoJ, CalcedoR, et al.Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets. Hum Gene Ther, 2007; 18:185–194.
27.
LiH, MurphySL, Giles-DavisW, et al.Pre-existing AAV capsid-specific CD8+T cells are unable to eliminate AAV-transduced hepatocytes. Mol Ther, 2007; 15:792–800.
28.
LiH, LinSW, Giles-DavisW, et al.A preclinical animal model to assess the effect of pre-existing immunity on AAV-mediated gene transfer. Mol Ther, 2009; 17:1215–1224.
29.
EastmanSJ, BaskinKM, HodgesBL, et al.Development of catheter-based procedures for transducing the isolated rabbit liver with plasmid DNA. Hum Gene Ther, 2002; 13:2065–2077.
30.
AlinoSF, HerreroMJ, NogueraI, et al.Pig liver gene therapy by noninvasive interventionist catheterism. Gene Ther, 2007; 14:334–343.
31.
AiutiA, CattaneoF, GalimbertiS, et al.Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med, 2009; 360:447–458.
32.
Hacein-Bey-AbinaS, Le DeistF, CarlierF, et al.Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med, 2002; 346:1185–1193.
CartierN, Hacein-Bey-AbinaS, BartholomaeCC, et al.Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science, 2009; 326:818–823.
35.
GrossmanM, RaperSE, KozarskyK, et al.Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet, 1994; 6:335–341.
36.
WisseE, JacobsF, TopalB, et al.The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer. Gene Ther, 2008; 15:1193–1199.
37.
Brunetti-PierriN, PalmerDJ, ManeV, et al.Increased hepatic transduction with reduced systemic dissemination and proinflammatory cytokines following hydrodynamic injection of helper-dependent adenoviral vectors. Mol Ther, 2005; 12:99–106.
38.
LievensJ, SnoeysJ, VekemansK, et al.The size of sinusoidal fenestrae is a critical determinant of hepatocyte transduction after adenoviral gene transfer. Gene Ther, 2004; 11:1523–1531.
39.
SnoeysJ, LievensJ, WisseE, et al.Species differences in transgene DNA uptake in hepatocytes after adenoviral transfer correlate with the size of endothelial fenestrae. Gene Ther, 2007; 14:604–612.
40.
Van DijkR, Montenegro-MirandaPS, RiviereC, et al.Polyinosinic acid blocks adeno-associated virus macrophage endocytosis in vitro and enhances adeno-associated virus liver-directed gene therapy in vivo. Hum Gene Ther, 2013; 24:807–813.
41.
TaoN, GaoGP, ParrM, et al.Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther, 2001; 3:28–35.
42.
GhoshA, AllamarvdashtM, PanCJ, et al.Long-term correction of murine glycogen storage disease type Ia by recombinant adeno-associated virus-1-mediated gene transfer. Gene Ther, 2006; 13:321–329.
43.
MerrittJL2nd, NguyenT, DanielsJ, et al.Biochemical correction of very long-chain acyl-CoA dehydrogenase deficiency following adeno-associated virus gene therapy. Mol Ther, 2009; 17:425–429.
44.
NyhanWL, GargusJJ, BoyleK, et al.Progressive neurologic disability in methylmalonic acidemia despite transplantation of the liver. Eur J Pediatr, 2002; 161:377–379.
45.
MeyburgJ, HoffmannGF. Liver transplantation for inborn errors of metabolism. Transplantation, 2005; 80:S135–S137.
46.
MckiernanP. Liver transplantation and cell therapies for inborn errors of metabolism. J Inherit Metab Dis, 2013; 36:675–680.
47.
FagiuoliS, DainaE, D'AntigaL, et al.Monogenic diseases that can be cured by liver transplantation. J Hepatol, 2013; 59:595–612.
48.
Brunetti-PierriN, LeeB. Gene therapy for inborn errors of liver metabolism. Mol Genet Metab, 2005; 86:13–24.
49.
CotugnoG, AnnunziataP, TessitoreA, et al.Long-term amelioration of feline Mucopolysaccharidosis VI after AAV-mediated liver gene transfer. Mol Ther, 2011; 19:461–469.
50.
HindererC, BellP, GurdaBL, et al.Liver-directed gene therapy corrects cardiovascular lesions in feline mucopolysaccharidosis type I. Proc Natl Acad Sci USA, 2014; 111:14894–14899.
51.
BatshawML, TuchmanM, SummarM, et al.A longitudinal study of urea cycle disorders. Mol Genet Metab, 2014; 113:127–130.
52.
MoscioniD, MorizonoH, MccarterRJ, et al.Long-term correction of ammonia metabolism and prolonged survival in ornithine transcarbamylase-deficient mice following liver-directed treatment with adeno-associated viral vectors. Mol Ther, 2006; 14:25–33.
53.
CunninghamSC, KokCY, DaneAP, et al.Induction and prevention of severe hyperammonemia in the spfash mouse model of ornithine transcarbamylase deficiency using shRNA and rAAV-mediated gene delivery. Mol Ther, 2011; 19:854–859.
54.
KokCY, CunninghamSC, CarpenterKH, et al.Adeno-associated virus-mediated rescue of neonatal lethality in argininosuccinate synthetase-deficient mice. Mol Ther, 2013; 21:1823–1831.
55.
WangL, BellP, LinJ, et al.AAV8-mediated hepatic gene transfer in infant rhesus monkeys (Macaca mulatta). Mol Ther, 2011; 19:2012–2020.
56.
CoppolettaJM, WolbachSB. Body length and organ weights of infants and children: a study of the body length and normal weights of the more important vital organs of the body between birth and twelve years of age. Am J Pathol, 1933; 9:55–70.
57.
ChandlerRJ, LafaveMC, VarshneyGK, et al.Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J Clin Invest, 2015; 125:870–880.
58.
DonsanteA, MillerDG, LiY, et al.AAV vector integration sites in mouse hepatocellular carcinoma. Science, 2007; 317:477.
59.
LiH, MalaniN, HamiltonSR, et al.Assessing the potential for AAV vector genotoxicity in a murine model. Blood, 2011; 117:3311–3319.
60.
NiemeyerGP, HerzogRW, MountJ, et al.Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood, 2009; 113:797–806.
61.
NathwaniAC, RosalesC, McintoshJ, et al.Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther, 2011; 19:876–885.
62.
StraussKA, RobinsonDL, VremanHJ, et al.Management of hyperbilirubinemia and prevention of kernicterus in 20 patients with Crigler-Najjar disease. Eur J Pediatr, 2006; 165:306–319.
63.
FoxIJ, ChowdhuryJR, KaufmanSS, et al.Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation. N Engl J Med, 1998; 338:1422–1426.
64.
PastoreN, NuscoE, PiccoloP, et al.Improved efficacy and reduced toxicity by ultrasound-guided intrahepatic injections of helper-dependent adenoviral vector in Gunn rats. Hum Gene Ther Methods, 2013; 24:321–327.
65.
ChowdhuryJR, KondapalliR, ChowdhuryNR. Gunn rat: a model for inherited deficiency of bilirubin glucuronidation. Adv Vet Sci Comp Med, 1993; 37:149–173.
66.
BortolussiG, ZentilinL, BajG, et al.Rescue of bilirubin-induced neonatal lethality in a mouse model of Crigler-Najjar syndrome type I by AAV9-mediated gene transfer. FASEB J, 2012; 26:1052–1063.
67.
MirandaPS, BosmaPJ. Towards liver-directed gene therapy for Crigler-Najjar syndrome. Curr Gene Ther, 2009; 9:72–82.
68.
BortolussiG, ZentillinL, VanikovaJ, et al.Life-long correction of hyperbilirubinemia with a neonatal liver-specific AAV-mediated gene transfer in a lethal mouse model of Crigler-Najjar Syndrome. Hum Gene Ther, 2014; 25:844–855.
69.
Montenegro-MirandaPS, PanedaA, Ten BloemendaalL, et al.Adeno-associated viral vector serotype 5 poorly transduces liver in rat models. PLoS One, 2013; 8:e82597.
70.
WidhalmK, BinderCB, KreisslA, et al.Sudden death in a 4-year-old boy: a near-complete occlusion of the coronary artery caused by an aggressive low-density lipoprotein receptor mutation (W556R) in homozygous familial hypercholesterolemia. J Pediatr, 2011; 158:167.
71.
SnidermanAD, TsimikasS, FazioS. The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies. J Am Coll Cardiol, 2014; 63:1935–1947.
72.
LebherzC, GaoG, LouboutinJP, et al.Gene therapy with novel adeno-associated virus vectors substantially diminishes atherosclerosis in a murine model of familial hypercholesterolemia. J Gene Med, 2004; 6:663–672.
73.
KassimSH, LiH, BellP, et al.Adeno-associated virus serotype 8 gene therapy leads to significant lowering of plasma cholesterol levels in humanized mouse models of homozygous and heterozygous familial hypercholesterolemia. Hum Gene Ther, 2013; 24:19–26.
74.
ChenSJ, SanmiguelJ, LockM, et al.Biodistribution of AAV8 vectors expressing human low-density lipoprotein receptor in a mouse model of homozygous familial hypercholesterolemia. Hum Gene Ther Clin Dev, 2013; 24:154–160.
75.
CuchelM, MeagherEA, Du Toit TheronH, et al.Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet, 2013; 381:40–46.
76.
RaalFJ, SantosRD, BlomDJ, et al.Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet, 2010; 375:998–1006.
77.
LeumannE, HoppeB. The primary hyperoxalurias. J Am Soc Nephrol, 2001; 12:1986–1993.
78.
HoppeB, LangmanCB. A United States survey on diagnosis, treatment, and outcome of primary hyperoxaluria. Pediatr Nephrol, 2003; 18:986–991.
79.
CochatP, Koch NogueiraPC, MahmoudMA, et al.Primary hyperoxaluria in infants: medical, ethical, and economic issues. J Pediatr, 1999; 135:746–750.
80.
MillanMT, BerquistWE, SoSK, et al.One hundred percent patient and kidney allograft survival with simultaneous liver and kidney transplantation in infants with primary hyperoxaluria: a single-center experience. Transplantation, 2003; 76:1458–1463.
81.
CochatP, FaureJL, DivryP, et al.Liver transplantation in primary hyperoxaluria type 1. Lancet, 1989; 1:1142–1143.
82.
WattsRW, CalneRY, RollesK, et al.Successful treatment of primary hyperoxaluria type I by combined hepatic and renal transplantation. Lancet, 1987; 2:474–475.
83.
SalidoE, Rodriguez-PenaM, SantanaA, et al.Phenotypic correction of a mouse model for primary hyperoxaluria with adeno-associated virus gene transfer. Mol Ther, 2011; 19:870–875.
84.
BainbridgeJW, SmithAJ, BarkerSS, et al.Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med, 2008; 358:2231–2239.
85.
YinH, XueW, ChenS, et al.Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol, 2014; 32:551–553.
